Cassava Sciences discloses CEO Richard Barry compensation: $675k base, 600k options at $27.42

FILANA THERAPEUTICS, INC.

Base salary $675,000, retroactive to July 15, 2024; annual bonus target 60% of base salary.
Stock option award of 600,000 shares at $27.42 exercise price; vests 25% annually starting July 15, 2025.
Termination without cause or for good reason triggers 12-month base salary continuation plus health benefits.
Options granted under 2018 Omnibus Equity Incentive Plan; change-in-control triggers same severance.
Agreement includes standard confidentiality, non-disclosure, and mandatory arbitration provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.